Laidlaw analyst Yale Jen initiated coverage of IN8bio with a Buy rating and $7.50 price target. IN8bio is an a clinical stage biotech company focusing on developing gamma-delta T cell-based cancer therapies, the analyst tells investors in a research note. The firm believes the company has “novel and well-differentiated” treatment approaches versus peers, supported by “very promising” initial clinical results from its two lead assets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INAB:
- IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
- IN8bio initiated with a Buy at JonesResearch
- Is INAB a Buy, Before Earnings?
- IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
- IN8bio announces publication on gamma-delta t cell therapy
